Health and Healthcare

Bristol Myers Squibb : BMY

All Bristol Myers Squibb Articles

596 Articles

Chris Lange | Feb 12, 2018 at 9:35 AM EST

Short Sellers Can’t Make Up Their Minds on Major Pharma

The January 31 short interest data have been compared with the previous figures, and short interest moves in these selected…

Lee Jackson | Feb 8, 2018 at 8:15 AM EST

JPMorgan Likes Big Cap Pharmaceutical Stocks as Market Volatility Jumps

Four large-cap pharmaceutical leaders are rated Overweight at JPMorgan, and all make sense for growth accounts looking for some safety…

Paul Ausick | Feb 5, 2018 at 10:35 AM EST

Bristol-Myers Squibb Earnings, Trial Results Not Enough to Please Investors

Fourth-quarter and full-year earnings at Bristol-Myers Squibb beat estimates, but a report of the successful trial of the company's lung…

Chris Lange | Feb 4, 2018 at 10:25 AM EST

Disney, Tesla, Twitter and More Earnings Coming This Week

24/7 Wall St. has put together a preview of Disney, General Motors, Twitter and other major companies scheduled to report…

Chris Lange | Jan 25, 2018 at 10:10 AM EST

Major Pharma Short Interest Keeps Climbing

The January 12 short interest data have been compared with the previous figures, and short interest in most of these…

Lee Jackson | Jan 25, 2018 at 10:00 AM EST

SunTrust Bullish on Blue Chip Large-Cap Pharmaceuticals: 4 to Buy Now

With the market trading at very extended valuations, and the S&P 500 on the longest streak ever without a 5%…

Chris Lange | Jan 11, 2018 at 9:45 AM EST

Major Pharma Short Interest Takes a Plunge

The December 29 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Jan 6, 2018 at 8:55 AM EST

20 More Biopharma Catalysts Coming in 2018

Credit Suisse has put together a list of biopharma companies in its coverage universe that stand to make significant moves…

Chris Lange | Dec 28, 2017 at 10:25 AM EST

More and More Short Sellers Raising the Stakes in Major Pharma

The December 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical…

Chris Lange | Dec 12, 2017 at 10:40 AM EST

Short Sellers Can’t Make Up Their Minds on Major Pharma

The November 30 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical…

Jon C. Ogg | Dec 6, 2017 at 10:05 AM EST

2018 Outlook: Biotech Stocks Looking Strong for Value and Growth Investors

It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately,…

Chris Lange | Nov 10, 2017 at 11:25 AM EST

Short Sellers Back Way Off Major Pharma

The October 31 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical…

Chris Lange | Oct 28, 2017 at 10:05 AM EDT

Top Biopharma Events Coming by the End of 2017

24/7 Wall St. has collected a few pharma and biotech catalysts that are coming up on the calendar in November…

Chris Lange | Oct 25, 2017 at 10:20 AM EDT

Short Sellers Hike Bets in Major Pharma

The October 13 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Oct 22, 2017 at 10:45 AM EDT

Celgene, Gilead, Biogen and More Major Biopharmas Reporting This Week

At least eight large biotech and pharma outfits are scheduled to report their latest earnings and revenues this coming week.

1 … 17 18 19 20 21 … 40

Bristol Myers Squibb : BMY

All Bristol Myers Squibb Articles

Short Sellers Can’t Make Up Their Minds on Major Pharma

JPMorgan Likes Big Cap Pharmaceutical Stocks as Market Volatility Jumps

Bristol-Myers Squibb Earnings, Trial Results Not Enough to Please Investors

Disney, Tesla, Twitter and More Earnings Coming This Week

Major Pharma Short Interest Keeps Climbing

SunTrust Bullish on Blue Chip Large-Cap Pharmaceuticals: 4 to Buy Now

Major Pharma Short Interest Takes a Plunge

20 More Biopharma Catalysts Coming in 2018

More and More Short Sellers Raising the Stakes in Major Pharma

Short Sellers Can’t Make Up Their Minds on Major Pharma

2018 Outlook: Biotech Stocks Looking Strong for Value and Growth Investors

Short Sellers Back Way Off Major Pharma

Top Biopharma Events Coming by the End of 2017

Short Sellers Hike Bets in Major Pharma

Celgene, Gilead, Biogen and More Major Biopharmas Reporting This Week

A $1.8 Million Portfolio, Two Withdrawal Plans: One Triggers IRMAA and RMD Taxes, One Never Does

Math Doesn’t Have Feelings: Dave Ramsey to a Debt-Free Caller Who Feels Like He Has Only $300 Left a Week on $105,000

NVDL’s 2x Promise Delivered Only 17.21% While NVIDIA Soared 22.21% in One Year

A $1.8 Million Portfolio, Two Withdrawal Plans: One Triggers IRMAA and RMD Taxes, One Never Does

Math Doesn't Have Feelings: Dave Ramsey to a Debt-Free Caller Who Feels Like He Has Only $300 Left a Week on $105,000

A $1.8 Million Portfolio, Two Withdrawal Plans: One Triggers IRMAA and RMD Taxes, One Never Does

Math Doesn’t Have Feelings: Dave Ramsey to a Debt-Free Caller Who Feels Like He Has Only $300 Left a Week on $105,000

Bristol Myers Squibb : BMY

All Bristol Myers Squibb Articles

Short Sellers Can’t Make Up Their Minds on Major Pharma

JPMorgan Likes Big Cap Pharmaceutical Stocks as Market Volatility Jumps

Bristol-Myers Squibb Earnings, Trial Results Not Enough to Please Investors

Disney, Tesla, Twitter and More Earnings Coming This Week

Major Pharma Short Interest Keeps Climbing

SunTrust Bullish on Blue Chip Large-Cap Pharmaceuticals: 4 to Buy Now

Major Pharma Short Interest Takes a Plunge

20 More Biopharma Catalysts Coming in 2018

More and More Short Sellers Raising the Stakes in Major Pharma

Short Sellers Can’t Make Up Their Minds on Major Pharma

2018 Outlook: Biotech Stocks Looking Strong for Value and Growth Investors

Short Sellers Back Way Off Major Pharma

Top Biopharma Events Coming by the End of 2017

Short Sellers Hike Bets in Major Pharma

Celgene, Gilead, Biogen and More Major Biopharmas Reporting This Week

A $1.8 Million Portfolio, Two Withdrawal Plans: One Triggers IRMAA and RMD Taxes, One Never Does

Math Doesn’t Have Feelings: Dave Ramsey to a Debt-Free Caller Who Feels Like He Has Only $300 Left a Week on $105,000

NVDL’s 2x Promise Delivered Only 17.21% While NVIDIA Soared 22.21% in One Year

Featured Reads

A $1.8 Million Portfolio, Two Withdrawal Plans: One Triggers IRMAA and RMD Taxes, One Never Does

Math Doesn't Have Feelings: Dave Ramsey to a Debt-Free Caller Who Feels Like He Has Only $300 Left a Week on $105,000